Lyell Immunopharma (NASDAQ:LYEL – Get Free Report) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday, Wall Street Zen reports.
Several other equities research analysts also recently issued reports on LYEL. HC Wainwright restated a “buy” rating on shares of Lyell Immunopharma in a research report on Friday. Needham & Company LLC reissued a “buy” rating and set a $44.00 price objective on shares of Lyell Immunopharma in a report on Friday. B. Riley Financial initiated coverage on Lyell Immunopharma in a report on Wednesday, July 22nd. They set a “buy” rating and a $44.00 price objective on the stock. Royal Bank Of Canada set a $34.00 target price on Lyell Immunopharma in a research note on Friday, August 14th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Lyell Immunopharma in a report on Friday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Lyell Immunopharma presently has an average rating of “Moderate Buy” and an average target price of $40.86.
View Our Latest Report on Lyell Immunopharma
Lyell Immunopharma Price Performance
Lyell Immunopharma (NASDAQ:LYEL – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($1.92) EPS for the quarter, topping the consensus estimate of ($1.94) by $0.02. Lyell Immunopharma had a negative net margin of 920,285.25% and a negative return on equity of 91.62%. The company had revenue of $0.00 million during the quarter, compared to the consensus estimate of $0.00 million. Equities analysts expect that Lyell Immunopharma will post -7.2 EPS for the current year.
Hedge Funds Weigh In On Lyell Immunopharma
A number of large investors have recently modified their holdings of LYEL. ARCH Venture Management LLC raised its stake in shares of Lyell Immunopharma by 51.5% during the third quarter. ARCH Venture Management LLC now owns 2,759,072 shares of the company’s stock worth $44,807,000 after acquiring an additional 938,438 shares in the last quarter. GSK plc purchased a new stake in shares of Lyell Immunopharma in the 4th quarter valued at $46,560,000. MWG Caph Ltd bought a new position in shares of Lyell Immunopharma during the 4th quarter valued at $31,030,000. Vanguard Group Inc. raised its position in Lyell Immunopharma by 76.0% in the 3rd quarter. Vanguard Group Inc. now owns 779,004 shares of the company’s stock worth $12,651,000 after purchasing an additional 336,378 shares during the period. Finally, Acadian Asset Management LLC lifted its stake in Lyell Immunopharma by 204.2% in the first quarter. Acadian Asset Management LLC now owns 660,899 shares of the company’s stock worth $354,000 after purchasing an additional 443,614 shares during the last quarter. 66.05% of the stock is owned by hedge funds and other institutional investors.
About Lyell Immunopharma
Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.
The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.
Read More
- Five stocks we like better than Lyell Immunopharma
- Why Bitcoin ETFs May Be Worth Another Look as Inflows Rebound
- 3 Small-Cap Biotechs With Binary Catalysts on the Calendar
- Planet Labs Has Fallen Back to Earth, But Wall Street Still Sees a Rebound
- As Homeowners’ Premiums Surge, This Insurer Is Posting Record Profits
Receive News & Ratings for Lyell Immunopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyell Immunopharma and related companies with MarketBeat.com's FREE daily email newsletter.
